



ISSN : 2347 - 2243

*Indo - American Journal of
Life Sciences and Biotechnology*



www.iajlb.com
Email : editor@iajlb.com or iajlb.editor@gmail.com



A RECENT TRENDS IN NANOPARTICULATE DRUG DELIVERY SYSTEM: MANUFACTURING ASPECTS, EVALUATION PARAMENTERS

¹Ms. T. Chaitanya Kumari, ²Mr. Ch. Kishore, ³Mrs. M. Sandhya Rani

^{1,3}Assistant Professor, ²Associate Professor

^{1,2,3}Department of Pharmaceutics

Vaagdevi Institute of Pharmaceutical Sciences, Bollikunta, Warangal. Telangana.

ABSTRACT

A relatively new and rapidly developing field, nanomedicine and nano-delivery systems use materials at the nanoscale for targeted, controlled delivery of medicinal medicines as well as diagnostic instruments. With the ability to precisely and specifically distribute therapeutic molecules to specified sites, nanotechnology has significant benefits for the treatment of chronic illnesses. Current uses include a wide range of nanomedicine applications, including as biological, immunotherapeutic, and chemotherapeutic drugs for treating various medical ailments.

An updated synopsis of current developments in the fields of nanomedicines and nano-based drug delivery systems is given in this thorough analysis. It critically looks at how nanomaterials are used to identify disease marker molecules, which allows for selective illness detection, and to improve the efficacy of both new and old medications (such as natural products). The paper also discusses the opportunities and difficulties involved in bringing nanomedicines from natural or synthetic sources to actual clinical use.

The paper also provides insights into current developments and potential future directions in the field of nanomedicine.

KEYWORDS:

nanotechnology, nanomedicines, nano drug delivery systems (NDDSs), and NDDS targeting approach.

I. INTRODUCTION

Nanotechnology is the deliberate engineering and manipulation of particulate matter into a physical state that is between 1 nm and 100 nm, which may then be reorganized or reassembled into nano-systems with increased function [1]. The potential uses of nanoparticles and nanomaterials in medicine are being investigated more and more. The field of drug delivery stands out as a highly captivating and promising area of application. The nano drug delivery system is one such groundbreaking invention that makes use of nanotechnology to boost treatment efficacy, decrease adverse effects, and improve drug delivery efficiency [2].

A drug delivery system (DDS) is defined as “a formulation or a device that enables the introduction of a therapeutic substance into the body and improves its efficacy and safety by controlling the rate, time, and place of release of drugs in the body” [3]. These systems offer enhanced drug bioavailability by improving drug solubility and stability, thereby maximizing therapeutic efficacy. Their ability to achieve targeted drug delivery to specific tissues, cells,



or subcellular compartments minimizes off-target effects and reduces systemic toxicity [4].

The global market for nano drug delivery is anticipated to reach a remarkable \$126.8 billion by 2026, growing at a 14.1% compound annual growth rate (CAGR) between 2021 and 2026, per Grand View Research[5]. The many benefits that nano drug delivery systems provide, such as improved bioavailability, prolonged drug release, targeted administration to particular cells or tissues, and the capacity to overcome biological barriers, may be credited for this exponential expansion[6].

Nano drug delivery systems help a lot in sustained and controlled drug release, enabling prolonged therapeutic activity, reduced dosing frequency, and improved patient compliance. Overcoming biological barriers, such as the blood-brain barrier, is another noteworthy advantage, as it allows drugs to reach previously inaccessible sites[7]. Additionally, nano drug delivery systems present opportunities for combination therapy, where multiple drugs or therapeutic agents can be encapsulated within a single nanoparticle, promoting synergistic effects and personalized treatment strategies[8]. Overall, the utilization of nano drug delivery systems holds great promise in enhancing therapeutic outcomes, mitigating adverse effects, and advancing the field of precision medicine[9].

Nano drug delivery systems have both organic and inorganic nanocarriers. Solid lipid nanoparticles, liposomes, dendrimers, polymeric nanoparticles, polymeric micelles, and virus-based nanoparticles are examples of organic nanocarriers. Carbon nanotubes and mesoporous silica nanoparticles are examples of inorganic nanoparticles. For instance, liposomes, a type of nano drug delivery system, have been

extensively explored[10]. Doxil, a liposomal formulation of doxorubicin, showed improved efficacy and reduced cardiotoxicity compared to the free drug, leading to its approval for the treatment of ovarian cancer and AIDS-related Kaposi's sarcoma[11].

Despite their potential, nano drug delivery systems face certain challenges that need to be addressed for their successful translation into clinical applications[12]. The stability and storage of nano drug delivery systems present additional challenges. The complex manufacturing and scale-up processes involved in ensuring consistent quality, reproducibility, and scalability of nanoparticles pose a significant challenge[13]. Establishing standardized guidelines for assessing safety, efficacy, and quality is essential for facilitating regulatory approval and market entry. Lastly, the high cost associated with nano drug delivery systems limits their widespread adoption. Developing cost-effective manufacturing processes and addressing economic feasibility are necessary to improve accessibility[14].

II. TYPES OF THE NDDSS

Liposomes, dendrimers, carbon nanomaterials, fullerenes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers, nano shells, quantum dots, superparamagnetic nanoparticles, and others are examples of the many morphologies of nanoparticles[15]. The description, importance, and challenges of these different morphologies of nanoparticles as drug delivery systems are given below:

2.1. Liposomes

Liposomes are colloidal particles enclosed by lipid bilayers, formed by self-assembly of amphiphilic phospholipids. They have sizes ranging from 25 nm to 200 nm and are often



used in drug delivery, particularly targeting cancer cells. Liposomes were discovered in 1965 and have been utilized as drug delivery systems since 1971[16]. The hydrophobic effect drives their bilayer structure formation. Liposomes can evade opsonization by the reticuloendothelial system when PEG is added to their surface. Doxil, a liposomal medication, was the first FDA-approved nanotechnology product for cancer treatment. Liposomes have the advantage of delivering both biological macromolecules like DNA and smaller molecules[17].

2.1.1. Types of liposomes

Liposomes are widely used in pharmaceutical and cosmetic industries as carriers for drug delivery. They offer advantages such as membrane-like structure, drug stability, improved biodistribution, and compatibility with hydrophilic and hydrophobic drugs[18]. There are four categories for liposomes:

- 1) Traditional liposomes are composed of an aqueous core and a lipid bilayer that may contain neutral, cationic, or anionic cholesterol and phospholipids. In this case, the lipid bilayer and the aqueous space can be filled with either hydrophobic or hydrophilic substances.
- 2) PEGylated types: The surface of the liposome is coated with polyethylene glycol (PEG) to create steric equilibrium.
- 3) Ligand-targeted type: Ligands are connected to the surface of the liposome or to the end of PEG chains that have previously been attached. Ligands include peptides, sugars, and antibodies.
- 4) The fourth liposome type is known as a theragnostic liposome and incorporates the first three liposome types. It frequently contains a nanoparticle as well as a therapeutic, imaging, and targeting component[19].

The normal production process includes thin layer hydration, mechanical agitation, solvent

evaporation, solvent injection, and surfactant solubilization[20].

2.1.2. Liposome as drug delivery systems

Due to their exceptional qualities, liposomes have been widely researched for their use in medicine delivery to malignant and tumor tissues using two main methods: passive targeting and active targeting as shown in Figure 1[21].




Figure 1. Passive targeting and active targeting. Liposomes can be surface functionalized to dedicate stealth through PEGylation and to meliorate receptor mediated endocytosis by utilizing targeting ligands such as antibodies, peptides, proteins, carbohydrates, Aptamer, and various other small molecules. PEGylation prolongs liposomal circulation half-life in vivo. Types of drugs based on whether they are hydrophobic or hydrophilic can be encapsulated into the aqueous lumen, incorporated into the lipid bilayer, or conjugated to the liposome surface[22].

Passive targeting is based on the physical features of the tumor and the magnitude of the nanomaterials. Cancer cells overexpress vascular endothelial growth factor (VEGF), which causes an excessive amount of angiogenesis. The proper size of liposomes may flow in the bloodstream for a longer duration, allowing the anti-tumor drug nano system to concentrate on the tumor tissue. Tumor tissue has bigger vascular holes than normal ones[23].



When a drug delivery system accesses malignant tissue, nanoparticle retention durations rise due to anomalies in the lymphatic system, which is not conceivable for tiny drug molecule[24].

This process involves further coating the nanoparticle with a biocompatible PEG polymer, which allows it to escape the reticuloendothelial (RES) system as well as prolongs the duration blood circulates in the circulatory system; PEG has this effect by shielding liposomes from opsonization[25].

In photodynamic treatment (PDT), light is used to activate photosensitizing drugs, producing reactive oxygen species (ROS) or singlet oxygen which destroy tumors. PDT was first employed for bladder cancer and has since been researched for usage in other cancers[26]. By encapsulating photosensitizers, nanocarriers can increase PDT by increasing the bioavailability and stability of the photosensitizers. However, due to the limited light penetration, PDT is only effective on surface tumors. Limitations such as low bioavailability, hydrophobic adverse effects, high dosage requirements, and self-aggregation in aqueous media are addressed by nanocarriers. They show promise for raising PDT effectiveness[27].

Liposomes are versatile carriers for drugs, being able to transport both water and lipid-soluble drugs due to their amphiphilic and non-ionic structure[28]. Researchers can manipulate their permeability, stiffness, size, and surface functionalization to create sustained and targeted drug delivery systems[29]. Liposomal delivery addresses the need for biodegradable drug delivery and prevents drug oxidation[30].

Despite their benefits, liposome-based structures have drawbacks that prevent widespread clinical application. Their physical and chemical stability, low solubility in aqueous solutions,

short half-life in the body, high production costs, and allergic reactions to specific liposomal chemicals are the key challenges[31].

2.2. Carbon nanomaterials

DNA's basic building block, carbon, is responsible for the creation of all life on earth. Due to its unique electron configuration (1s², 2s², 2p), it can be found in a variety of forms[32]. Due to its capacity to bind itself and practically all elements, it has a wide range of technical uses, including the transport of pharmaceuticals and synthetic materials[33].

CBNs are divided into carbon nanotubes, graphene, mesoporous carbon, nanodiamonds, and fullerenes based on their structural differences. These materials have enhanced drug-loading capacity, biocompatibility, and immunogenicity[34]. It has been possible to create biocompatible scaffolds and nanomedicines using functionalized CBNs. Due to their superior supramolecular stacking, high adsorption capacity, and photothermal conversion capacity, they have been investigated for cancer therapy[35]. Therapy can be improved by combining chemical functionalization with adaptive characteristics.

2.3. Carbon nanotubes

Carbon nanotubes (CNTs) are tubes or cylinders with a special blend of stiffness, elasticity, and strength. Single-walled nanotubes (SWCNTs) are elongated folded graphene sheets that were created through sp² hybridization and have one-dimensional hollow and cylindrical forms. These CNTs have a diameter of roughly 1 nm and can grow to hundreds of times their original length[36].

Multi-walled carbon nanotubes (MWCNTs) are composed of many graphene sheet layers and have more complicated electrical properties.



Sizes of this type of nanotubes range from 5 nm to 50 nm[37].

Functionalized CNTs (f-CNTs) have improved solubility, biocompatibility, and reduced toxicity when tagged with functional groups or therapeutic molecules[38]. Covalent and non-covalent modifications are used to alter CNT surfaces, but they may affect mechanical strength[39].

The potential benefits of SWCNTs in metal nanoparticles, such as bulk medication loading, structural adaptability, inherent stability, enhanced circulation time, and bioavailability, have drawn attention among the many types of carbon nanotubes[40]. Higher drug loading is possible thanks to the ability of functionalized SWCNTs to entrap low molecular weight substances and antibodies. This also enables the conjugation of biological molecules without inducing an immunological response.

Doxorubicin (DOX) is commonly used in chemotherapy, but it has limitations, including side effects, low barrier crossing ability, and irreversible toxicity. Carbon nanotubes (CNTs) can effectively transport DOX, reducing side effects due to their high surface area, stability, and cell membrane penetration. In breast cancer treatment, amino-functionalized single-walled CNTs (NH₂-SWCNTs) combined with hyaluronic acid (HA) showed faster DOX release in the tumor cell environment. SWCNTs-DOX-HA reduced tumor cell growth and induced apoptosis more effectively than SWCNTsDOX alone, enhancing breast cancer treatment and the structure of doxorubicin (DOX) is shown in Figure 2[41].




Figure 2. Structure of doxorubicin (DOX) pH-responsive SWCNT-folic acid (FA) conjugates demonstrated higher drug loading and antitumor effects, reducing DOX side effects. FA-EDA-MWCNTs-DOX showed pH-dependent release and cytotoxicity against breast cancer cells[42].

2.4. Graphene

Graphene, a single layer of carbon with partially filled sp² -orbitals, possesses large surface area, superior thermal conductivity, optical clarity, and strong mechanical strength. It acts as a semiconductor, forming new quasi-particles upon interaction with electrons. Quantum dots and graphene nanoribbons enable ballistic transport without scattering[43].

Graphene exhibits good electrical conductivity and reduced solubility. Sol-gel chemistry allows for alterations like graphene oxide and layered graphene-oxide. Graphene and its derivatives have diverse applications in medicine and drug delivery, with polymer surface modification enhancing biocompatibility[44]. Graphene nanomaterials respond to stimuli, regulating drug release based on internal and environmental inputs, improving absorption, overcoming barriers, and minimizing side effects[45].

Because of the functional groups that are present on the side walls, GOs have attracted a lot of attention among graphene nanomaterials. DOX and camptothecin were captured by graphene



through hydrophobic interaction and π - π stacking. The presence of hydroxyl and carboxyl groups on the surface of GOs makes it easier for them to attach to the hydroxyl and amino groups of DOX[46].

A study using the 4T1 cancer cell lines showed that the electrochemical method successfully exhibited carrier capacity and cellular capacity. Based on pH-stimuli drug delivery, 5-fluorouracil loaded GO was created and the structure of 5-fluorouracil is shown in Figure 3[47].




Figure 3. Chemical structure of 5-fluorouracil. This formulation controlled the release of the anticancer agent in the tumors environment's acidic pH of 5.8, however the release was dramatically reduced in the physiological pH of 7.4.

III. MULTIFUNCTIONAL NANOPARTICLES AS NDDSS

As a result of their direct targeting of the damaged organs, metal nanoparticles allow drug delivery systems to minimize adverse effects.

3.1. Silver nanoparticles

The manufacture of NPs and nanoparticles uses silver, which is the precious metal with the highest profit-orientedness because of its antiviral, antifungal, and antioxidant properties. These are wellknown due to their unusually improved physicochemical properties relative to the bulk material, such as optical, thermal, electrical, and catalytic capabilities, as well as their anti-bacterial, anti-viral, antifungal, and antioxidant activities[48]. A variety of different

cell types have been shown to be susceptible to cytotoxicity caused by silver nanoparticles via apoptosis and necrosis. Additionally, they show results against side effects of conventional therapies such DNA damage, the production of reactive oxygen species (ROS), an increase in lactate dehydrogenase (LDH) leakage, and inhibition of stem cell differentiation[49].

3.2. Gold nanoparticles

AuNPs, also known as gold nanoparticles, are potent radiosensitizers used in medical operations such drug administration and cancer treatment[50]. Gold nanoparticles, or AuNPs, are potent radiosensitizers utilized in cancer treatment and drug administration. Au NPs are able to deliver a variety of pharmaceutical compounds, recombinant proteins, vaccines, or nucleotides into their targets thanks to their capacity to govern drug release via internal biological triggers or external light activation. Given its impressive effectiveness, AuNP-based drug delivery has drawn a lot of attention[51].

IV. TARGETING STRATEGY OF THE NDDSS

There are two mechanisms by which nanocarriers can deliver to target nano-drugs: active targeting and passive targeting. In active targeting, we focus on specific markers found only in sick cells, not healthy ones. For example, we can use molecules that interact with the overexpressed folate receptors in sick cells. CA-125 is an example of a biomarker overexpressed in ovarian cancer that can be actively targeted[52].

In passive targeting, the size of polymers is important. Larger polymers can accumulate more at the site of diseased cells. This happens because the polymers can pass through leaky blood vessel junctions and reach the sick area.

It's like taking advantage of the openings in the blood vessels to deliver the drugs where they are needed[53].

In Figure 4, the illustration of passive and active targeting of nanoparticles (NPs) for enhancing the therapeutic efficacy of anticancer drugs. Figure 4A: passive targeting of NPs taking advantage of the enhanced permeability and retention (EPR) effect; Figure 4B: active targeting of NPs attached with ligands to enhance accumulation and cellular uptake of NPs via receptor-facilitated endocytosis[54].




Figure 4. Passive and active targeting of nanoparticles (NPs) as a drug delivery system.

V. APPLICATION OF NDDSS

Nano drug delivery systems have various applications in medical field. Some are given below:

5.1. AuNPs in cancer therapy

For gold nanoparticles to be used as therapeutics, it is essential to comprehend how they are biodistributed and accumulate in living systems. This can only be done with accurate characterization of the nanomaterials, a reliable animal model, a sizeable sample, and strong statistical analyses. AuNPs regulate damage to healthy cells and lessen the likelihood of adverse outcomes[55]. AuNPs are a novel component in cancer therapy that display aggregation[56] and a size-dependent lethal effect on various cancer cells[57]. The anti-cancer action of AuNP is

complicated and poorly understood. The positive charges are on AuNPs, but cancerous and healthy cell membranes include molecules that are negatively charged, such as lipids, which cause AuNPs to be absorbed and internalized[58]. Another mechanism by which AuNPs enter cells is endocytosis, which results in the accumulation of tiny AuNPs inside HeLa cells[59].




Figure 5. Synthesis of PEG-AuNPs NPs (a) the chemical composition of DOX and BLM and the procedures involved in conjugating them to the surface of S1; (b) a schematic depicting the production of S2, S3, and S4 NPs.

We focused on the development of the following gold nanoparticles-based drug delivery systems: AuNPs covered by PEG carrying carboxylic groups, PEG-AuNPs linked to DOX, PEG-AuNPs linked to BLM, and, finally PEG-AuNPs linked to both DOX and BLM (referred to as S1, S2, S3 and S4, correspondingly) as illustrated in Figure 5[59].

5.2. AgNPs as anti-viral agents

A significant problem for the pharmaceutical, medical, and biotechnological industries is the development of resistance by different viral pathogens against anti-viral drugs[60]. Because of their successful interactions with sulfhydra, amino, carboxyl, phosphate, and imidazole groups, AgNPs are well acknowledged to suppress viruses.

Due to their inhibitory efficiency against a variety of viruses, including hepatitis, coronavirus, influenza, herpes, recombinant respiratory syncytial virus, and human immunodeficiency virus, AgNPs have recently gained popularity as anti-viral medicines[61]. AgNPs were employed to create a nanoscale delivery system for the antiviral drug zanamivir, and surface-enriching AgNPs with amantadine to prevent H1N1 virus resistance as demonstrated in Figure 6[62].




Figure 6. The reversal of H1N1 influenza virus-induced apoptosis by silver nanoparticles.

VI. CONCLUSION AND FUTURE PERSPECTIVES

VII.

Over the last two to three decades, the development and expansion of nanotechnology for therapeutic and medical-related applications has provided unparalleled prospects to create medical diagnosis and therapies for human illnesses. The nanomaterials demonstrate a high degree of control over the desired properties as

demonstrated by their enhanced solubility of a variety of cargoes, disease-fighting ability, controlled transmission, improved strength, increased biodistribution inside the organism, Modula table (adjust to certain proportion) means of transport across tissues and cells, and controlled delivery to the target location. These sorts of techniques may be used to create image components and detectors with higher sensitivity for analysis and identification. There are still other problems that need to be resolved before this study may produce medications that are therapeutically useful. Developing and evaluating novel techniques to regulate the interactions of nanoparticles with the body is a major obstacle to the commercialization of this technology. The challenge of delivering nanomaterials to targeted bodily areas without allowing organs like the liver and spleen to entrap them must be solved. Enhancement and modification of existing technologies have been possible via the manipulation of material properties at the nanoscale. Thus, the promise of medications based on nanotechnology may materialize with sufficient time and study.

REFERENCES

1. Nasrollahzadeh M, Saiadi SM, Sajjadi M, Issaabadi Z. An introduction to nanotechnology. In: Interface Science and Technology. Elsevier; 2019.
2. Doran J, Ryan G. Does nanotechnology research generate an innovation premium over other types of research? Evidence from Ireland. *Technology in Society* 2019; 59: 101183. doi: 10.1016/j.techsoc.2019.101183
3. Qiao L, Yang H, Gao S, et al. Research progress on self-assembled nanodrug



- delivery systems. *Journal of Materials Chemistry B* 2022; 10(12): 1908–1922. doi: 10.1039/D1TB02470A
4. Osman N, Devnarain N, Omolo CA, et al. Surface modification of nano-drug delivery systems for enhancing antibiotic delivery and activity. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology* 2022; 14(1): e1758. doi: 10.1002/wnan.1758
 5. Jain KK. An overview of drug delivery systems. In: Jain KK (editor). *Drug Delivery Systems*. Humana; 2019. Volume 2059, pp. 1–54.
 6. Wang Y, Sun T, Jiang C. Nanodrug delivery systems for ferroptosis-based cancer therapy. *Journal of Controlled Release* 2022; 344: 289–301. doi: 10.1016/j.jconrel.2022.01.034
 7. Wang C, Li F, Zhang T, et al. Recent advances in anti-multidrug resistance for nano-drug delivery system. *Drug Delivery* 2022; 29(1): 1684–1697. doi: 10.1080/10717544.2022.2079771
 8. Li R, Chen Z, Li J, et al. Nano-drug delivery systems for T cell-based immunotherapy. *Nano Today* 2022; 46: 101621. doi: 10.1016/j.nantod.2022.101621
 9. Ma Z, Li B, Peng J, Guo D. Recent development of drug delivery systems through microfluidics: From synthesis to evaluation. *Pharmaceutics* 2022; 14(2): 434. doi: 10.3390/pharmaceutics14020434
 10. Tian C, Zheng S, Liu X, Kamei K. Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system. *Journal of Nanobiotechnology* 2022; 20(1): 1–16. doi: 10.1186/s12951-022-01552-0